Calendario›INCY›INCB028050
INCB028050
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
Ensayo de INCYTE CORP en Artritis reumatoide.
Más ensayos de: Artritis reumatoide.
- Fase
- Fase 2
- Estado
- Completado
- Participantes
- 127
- Centros
- 49
- Fin del objetivo primario
- jun 2010
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, doble ciego. Comenzó en may 2009.
Qué mide
The Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Improvement (del registro, en inglés) (semana 12)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis was a randomized, double blind, placebo controlled, dose ranging, parallel group study. Participants who had active rheumatoid arthritis (RA) who had inadequate response to any disease modifying anti-rheumatic drug (DMARD) therapy including biologics were enrolled. Screening evaluations were performed within approximately 28 days of randomization. The duration of the study was 6 months with the primary endpoint assessed at 3 months. Eligible participants were randomly assigned to one of three doses (4, 7 or 10 mg QD) of INCB028050 (Baricitinib) or placebo.
Más ensayos de INCY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| tafasitamab · InMIND | Fase 3 | En marcha, sin reclutar | feb 2024 (real) |
| Tafasitamab · MINDway | Fase 1/2 | En marcha, sin reclutar | jul 2024 (real) |
| Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | no aplica | Reclutando pacientes | jun 2025 (prevista, ya pasada: sin actualizar en el registro) |
| tafasitamab · J-MIND | Fase 1/2 | En marcha, sin reclutar | jul 2025 (real) |
| INCA034176 | Fase 3 | En marcha, sin reclutar | ago 2025 (real) |
| Povorcitinib | Fase 3 | En marcha, sin reclutar | feb 2026 (real) |
Todos los de INCY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT00902486), actualizada en ago 2018.